ATP2B1

ATP2B1 (PMCA1) is a plasma membrane Ca²⁺-ATPase that actively extrudes cytoplasmic Ca²⁺ to maintain intracellular calcium homeostasis, serving essential roles in embryonic development, cardiovascular regulation, immune cell function, and neuronal health. In vascular smooth muscle cells, PMCA1 controls resting and agonist-stimulated Ca²⁺ levels, and its loss elevates blood pressure through increased vasoconstriction and compensatory L-type Ca²⁺ channel upregulation; in endothelial cells, it tonically suppresses Ca²⁺/calmodulin-dependent eNOS activation, thereby modulating NO production and insulin-mediated Akt signaling (PMID:22311909, PMID:24805951, PMID:29416109). PMCA1 is the sole functional PMCA isoform in B cells and is required for normal B-cell development, while its loss in CD4⁺ T cells causes hyperactivation and colitis; in the intestine, it mediates vitamin D–dependent active Ca²⁺ absorption essential for bone mineralization (PMID:33098669, PMID:38507609, PMID:26392310). De novo pathogenic missense variants in ATP2B1 cause neurodevelopmental delay (MRD66) through reduced Ca²⁺ export capacity and cytoplasmic mislocalization of the mutant protein, and biallelic loss-of-function variants additionally produce primary hypoparathyroidism (PMID:35358416, PMID:37926713).

1. 2000 Medium

   Before transcriptional regulation of ATP2B1 was understood, promoter-reporter studies showed that 1,25-dihydroxyvitamin D₃ transrepresses the PMCA1 promoter in a tissue-specific manner in osteoblasts, establishing that ATP2B1 expression is hormonally regulated at the transcriptional level.

   Evidence Luciferase reporter assays with promoter deletions and EMSA in ROS 17/2.8 osteoblasts vs. MDBK cells

   PMID:11062020

   Open questions at the time

   • The positive VDRE element was not mapped
   • Mechanism of transrepression (indirect vs. direct VDR involvement) unresolved
   • Single cell line study
2. 2004 High

   Demonstrating that PMCA1 is non-redundant with other PMCA isoforms, homozygous Atp2b1 knockout in mice was embryolethal, establishing an essential developmental role.

   Evidence Gene-targeted null mutation in mice

   PMID:15178683

   Open questions at the time

   • Embryonic stage and cause of lethality not fully characterized
   • Whether lethality is due to Ca²⁺ overload, signaling defects, or structural failure was unknown
3. 2006 High

   Addressing how PMCA1 is directed to specific membrane domains, a Leu-Ile motif in the 'b'-tail splice variant was shown to mediate basolateral sorting in hair cells, revealing isoform-specific polarized trafficking.

   Evidence Immunofluorescence localization and targeting assays in inner ear hair cells

   PMID:16803870

   Open questions at the time

   • Whether the same motif governs sorting in other polarized epithelia was not tested
   • Adaptor proteins recognizing the Leu-Ile motif not identified
4. 2007 High

   Identifying a regulatory partner, 14-3-3ε was shown to physically interact with PMCA1 and inhibit its Ca²⁺-pumping activity, establishing a protein–protein mechanism for PMCA1 functional modulation.

   Evidence Co-immunoprecipitation, GST pull-down, and aequorin-based Ca²⁺ assay in CHO cells

   PMID:18029012

   Open questions at the time

   • Binding site on PMCA1 not mapped
   • Physiological context for 14-3-3ε inhibition in vivo not established
   • Whether phosphorylation-dependent
5. 2012 High

   Conditional knockout and in vivo knockdown established that PMCA1 in vascular smooth muscle cells directly controls intracellular Ca²⁺ and blood pressure, mechanistically linking the GWAS-associated ATP2B1 locus to hypertension.

   Evidence VSMC-specific Cre-loxP KO with telemetric BP, Ca²⁺ imaging, and vascular ring assays; corroborated by systemic siRNA knockdown

   PMID:22311909 PMID:23666421

   Open questions at the time

   • Relative contribution of VSMC vs. endothelial PMCA1 to total BP effect not dissected in these studies
   • Human genetic validation for VSMC-specific mechanism lacking
6. 2014 High

   Heterozygous Atp2b1-null mice revealed an endothelial mechanism: reduced PMCA1 impairs eNOS Ser-1177 phosphorylation and NO production, showing PMCA1 regulates vascular tone through both smooth muscle Ca²⁺ handling and endothelial NO signaling.

   Evidence Heterozygous KO mice with telemetric BP, vascular ring assays ± NOS inhibitor, eNOS phosphorylation Western blot, NO measurement

   PMID:24805951

   Open questions at the time

   • The paradox that PMCA1 loss raises Ca²⁺ yet impairs Ca²⁺/calmodulin-dependent eNOS was not fully reconciled at this stage
7. 2015 High

   Intestine-specific Atp2b1 deletion demonstrated that PMCA1 is the rate-limiting basolateral Ca²⁺ pump for vitamin D–dependent active Ca²⁺ absorption, linking it to bone mineralization.

   Evidence Villin-Cre intestinal KO, DXA bone mineral density, intestinal Ca²⁺ transport assay ± 1,25(OH)₂D₃

   PMID:26392310

   Open questions at the time

   • Relative contribution of PMCA1 vs. NCX1 at the basolateral membrane not quantified
   • Whether dietary Ca²⁺ rescue is possible not tested
8. 2017 Medium

   Further mechanistic dissection showed that VSMC-specific PMCA1 loss upregulates L-type Ca²⁺ channels, explaining enhanced CCB sensitivity, and that in endothelial cells PMCA1 silencing activates a Ca²⁺/calmodulin/eNOS/Akt cascade affecting insulin signaling.

   Evidence Conditional KO mice with pharmacological antihypertensive testing; siRNA in HUVECs with Ca²⁺ imaging, Akt phosphorylation, and pathway inhibitors

   PMID:29046519 PMID:29104511

   Open questions at the time

   • L-type channel upregulation mechanism (transcriptional vs. trafficking) not defined
   • In vivo validation of endothelial insulin sensitivity link absent
9. 2018 Medium

   Basal tonic regulation of eNOS by PMCA1 was confirmed: PMCA1 silencing in endothelial cells increases calmodulin–eNOS interaction and NO production even without agonist stimulation, and heterozygous KO mice develop systemic hypocalcemia with reduced PTH and hypercalciuria.

   Evidence siRNA in HUVECs with NO/eNOS assays; heterozygous KO mice with serum Ca²⁺/PTH, urinary Ca²⁺

   PMID:29416109 PMID:29950683

   Open questions at the time

   • Whether hypocalcemia is primary (renal/intestinal Ca²⁺ loss) or secondary (PTH deficiency) not resolved
   • Single-lab findings for both
10. 2020 High

    B-cell-specific Atp2b1 KO revealed that PMCA1 is the sole PMCA isoform expressed in B cells and is required for normal B-cell development; its loss elevates basal and ER Ca²⁺ and depletes follicular, marginal zone, and B-1a cell populations.

    Evidence B-cell-specific conditional KO, flow cytometry, PMCA isoform Western blot, intracellular Ca²⁺ measurement

    PMID:33098669

    Open questions at the time

    • Whether B-cell functional defects (antibody responses, class switching) accompany the numerical reduction not assessed
    • Downstream Ca²⁺-dependent transcriptional programs not identified
11. 2022 High

    De novo ATP2B1 missense variants were established as the cause of a neurodevelopmental disorder (MRD66): all tested variants reduced Ca²⁺ export and showed cytoplasmic mislocalization, defining the human disease mechanism.

    Evidence Ca²⁺ imaging and confocal localization of 9 variants in HEK293 cells across 12 unrelated probands, structural modeling

    PMID:35358416

    Open questions at the time

    • Neuronal-specific consequences of variants not studied
    • Genotype–phenotype correlations across variant severity not established
    • Animal model recapitulation of neurodevelopmental phenotype not reported
12. 2023 Medium

    Biallelic ATP2B1 loss-of-function (compound heterozygous splice-site + missense) was shown to cause primary hypoparathyroidism alongside neurodevelopmental deficits, expanding the clinical spectrum of PMCA1 deficiency.

    Evidence Trio exome sequencing, RT-PCR showing NMD of splice variant, Ca²⁺ extrusion assay and immunoblotting in patient fibroblasts

    PMID:37926713

    Open questions at the time

    • Single family — replication needed
    • Whether parathyroid Ca²⁺ sensing defect or PTH secretion defect not mechanistically distinguished
13. 2024 Medium

    CD4⁺ T-cell-specific Atp2b1 KO caused spontaneous colitis with Th1/Th2 hyperactivation, establishing PMCA1 as a Ca²⁺-dependent brake on T-cell inflammatory signaling in the gut.

    Evidence CD4-Cre conditional KO mice, flow cytometry, colon histology, qPCR for T-bet/GATA3/TNFα

    PMID:38507609

    Open questions at the time

    • Whether regulatory T-cell function is impaired not tested
    • Ca²⁺/NFAT pathway involvement in T-cell hyperactivation not directly measured
14. 2024 Medium

    SARS-CoV-2 was shown to downregulate ATP2B1 via PI3K/Akt/FOXO3 axis, and pharmacological restoration of PMCA1 expression reduced viral replication, placing ATP2B1 in a host Ca²⁺ defense pathway exploited by the virus.

    Evidence SARS-CoV-2 infection model with PI3K/Akt inhibition, FOXO3 activity assays, Ca²⁺ measurement, viral replication assay

    PMID:38816514

    Open questions at the time

    • Whether this extends to other viruses not tested
    • Direct FOXO3 binding to ATP2B1 promoter not shown by ChIP

• Key unresolved questions include the structural basis for pathogenic variant mislocalization, neuronal-specific consequences of PMCA1 loss, the mechanism by which PMCA1 supports Norrin/FZD4 β-catenin signaling in CNS endothelium, and whether PMCA1 pharmacological modulation has therapeutic potential for hypertension or neurodevelopmental disorders.
• No high-resolution structure of human PMCA1 available
• Neuron-specific conditional KO phenotype not reported
• Norrin/FZD4 interaction mechanism from preprint awaits peer review
• No therapeutic PMCA1 activator validated in vivo